Skip to main
BMEA

BMEA Stock Forecast & Price Target

BMEA Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Biomea Fusion is a promising investment opportunity due to its unique approach in targeting beta-cell failure for type 2 diabetes patients with its lead candidate icovamenib, as well as the potential of its BMF-650 GLP agonist for difficult-to-treat diabetics. Their stock is recommended with a Market Outperform rating, as the company is financially stable and has a successful CEO with a history in the biotech industry. Additionally, the company's recent progress in both Phase 2 trials for icovamenib and potential Phase 1 trial for BMF-650 suggests a positive future outlook.

Bears say

Biomea Fusion is a clinical stage company with two key drug candidates, icovamenib and BMF-650, in development for diabetes, obesity, and other metabolic diseases. While Phase 2 data for icovamenib is expected in 4Q26, there are risks associated with data interpretation, as efficacy has been seen in small subgroups and dose-response may not be consistent. Additionally, the market for diabetes medications is crowded and competitive. Therefore, as a financial analyst, I have a negative outlook on Biomea Fusion's stock due to the uncertain potential for its key drug candidates and the challenging market conditions.

BMEA has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biomea Fusion Inc (BMEA) Forecast

Analysts have given BMEA a Strong Buy based on their latest research and market trends.

According to 3 analysts, BMEA has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biomea Fusion Inc (BMEA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.